prucalopride / Generic mfg. - LARVOL DELTA

Prucalopride for Cognitive Functioning in Schizophrenia (clinicaltrials.gov) - P=N/A | N=34 | Not yet recruiting | Sponsor: University of Pittsburgh | Trial completion date: Dec 2026 ➔ Dec 2028 | Trial primary completion date: Dec 2026 ➔ May 2028

Trial completion date • Trial primary completion date • CNS Disorders • Psychiatry • Schizophrenia

First Reported Case of MRI Performed on a Patient With Multiple Vibrant Vibrating Capsules In Situ (ACG 2026) - "She experienced ineffective responses or side-effects to multiple pharmacologic therapies including polyethylene glycol, senna, bisacodyl (oral and rectal), glycerin suppositories, magnesium salts, linaclotide, plecanatide, lubiprostone, prucalopride, and tenapanor. This report also highlights the need for improved screening for ingestible electronic devices prior to MRI. Figure: X-ray Showing 5 Vibrant Vibrating Capsules In Situ 1 Day After MRI"

Clinical • Constipation • Endocrine Disorders • Fibromyalgia • Gastroenterology • Gastrointestinal Disorder • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics

Adjunctive Use of Vibrating Capsule for Refractory Constipation in Autosomal Dominant Polycystic Kidney Disease With Severe Organomegaly (ACG 2026) - "He had failed or inadequately responded to lactulose, polyethylene glycol, magnesium citrate, bisacodyl, senna, mineral oil, enemas, suppositories, lubiprostone, prucalopride, fiber, linaclotide alone, plecanatide alone, and pelvic floor physical therapy. Figure: Figure 1b. Sagittal T2-weighted MRI demonstrates renomegaly along with stool-filled colon."

Autism Spectrum Disorder • Autosomal Dominant Polycystic Kidney Disease • Chronic Kidney Disease • CNS Disorders • Constipation • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Muscular Dystrophy • Myotonic Dystrophy • Nephrology • Pancreatic Cancer • Polycystic Kidney Disease • Renal Disease

Staying Ahead of Distal Intestinal Obstructive Syndrome in Cystic Fibrosis (ACG 2026) - "Home bowel regimen included polyethylene glycol 3350 (PEG) 34 g BID, linaclotide 290 g daily and PEG-electrolyte solution (PEG-ELS) weekly...Given her refractory obstruction, prucalopride and metoclopramide were trialed...Presence of thickened distal/terminal ileum. Large stool burden."

Constipation • Cystic Fibrosis • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Immunology • Infectious Disease • Respiratory Diseases • CFTR

Mechanism of Shengqing Jiangzhuo Granules in ameliorating chronic functional constipation with dampness obstruction and Qi stagnation pattern and associated hyperuricemia based on "gut-microbiota-barrier" axis (PubMed, Zhongguo Zhong Yao Za Zhi) - "Animals were divided into a normal group, a model group, Shengqing Jiangzhuo Granules groups with low, medium, and high doses, linagliptin group, and prucalopride succinate group. Moreover, the prescription can reverse gut microbiota dysbiosis, promote the proliferation of butyrate-producing microbiota(e.g., Faecalibacterium and Blautia), increase colonic butyrate content, activate the HIF-1α signaling pathway, and enhance the expression of tight junction proteins. In conclusion, this study gradually delves from holistic pharmacodynamics to microscopic mechanism, clarifying that the action mechanism of Shengqing Jiangzhuo Granules in exerting a multi-target and holistic improvement effect on chronic functional constipation with dampness obstruction and Qi stagnation pattern, as well as its associated hyperuricemia through regulating the "gut microbiota-butyrate-HIF-1α-intestinal barrier" axis, providing a scientific basis for its clinical popularization and..."

Journal • Constipation • Dyslipidemia • Endocrine Disorders • Gastroenterology • Gastrointestinal Disorder • Metabolic Disorders • HIF1A • OCLN • TJP1

Prucalopride repurposing: 5-HT4 receptor agonists in anxiety and depression. (PubMed, Encephale) - "Converging evidence from animal models, experimental human studies, and epidemiological analyses suggest that prucalopride may modulate mood-related neural circuits and cognitive processes. This perspective discusses the translational potential of 5-HT4 receptor agonism as a novel therapeutic avenue for mood disorders."

Journal • CNS Disorders • Constipation • Depression • Gastroenterology • Gastrointestinal Disorder • Major Depressive Disorder • Mood Disorders • Psychiatry

Scleroderma, Stasis, and Sarcina: A Rare Gastric Infection in Systemic Sclerosis (ACG 2026) - "Case Description/ A 70-year-old woman with systemic sclerosis complicated by esophageal aperistalsis, and chronic use of methadone and trazodone presented with progressive dysphagia and reflux...She was treated with amoxicillin-clavulanate, high-dose proton pump inhibitor, and prucalopride as a prokinetic agent...Although ciprofloxacin plus metronidazole is the most commonly reported regimen, no formal treatment guidelines exist. In vitro susceptibility data suggest efficacy of penicillins, fluoroquinolones, macrolides, and tetracyclines. Our use of amoxicillin-clavulanate to avoid QT prolongation risk represents a novel therapeutic approach. This case highlights the importance of evaluating for underlying causes of delayed gastric emptying when S. ventriculi is detected, the variable clinical spectrum of this organism, and the role of individualized antibiotic selection when standard regimens are contraindicated."

Gastrointestinal Disorder • Immunology • Infectious Disease • Respiratory Diseases • Scleroderma • Systemic Sclerosis

The Contemporary "Balloon Man" Phenotype: A Giant Fecaloma in a Patient on Chronic Antipsychotics (ACG 2026) - "Psychiatry transitioned him from clozapine and olanzapine to haloperidol without breakthrough psychosis. He was discharged on prucalopride, polyethylene glycol, bisacodyl, and lactulose...Figure: Fig 2. Prior flexible sigmoidoscopy showing 2-3 cm clean-based rectosigmoid ulcers, consistent with chronic stercoral pressure injury from recurrent fecal loading."

Clinical • Acute Kidney Injury • CNS Disorders • Constipation • Endocrine Disorders • Gastroenterology • Gastrointestinal Disorder • Immunology • Mental Retardation • Nephrology • Renal Disease • Schizophrenia

Pan-Enteric Dysmotility and Small Bowel Malabsorption: A Multidisciplinary Challenge in a Patient With LADA and Hashimoto's (ACG 2026) - "Despite extensive medical therapy which included prokinetics (prucalopride, erythromycin, azithromycin) , intestinal secretagogues (lubiprostone, plecanatide), antiemetics (ondansetron, prochlorperazine) and antispasmodics (dicyclomine), (proton pump inhibitors and H2 blockers), symptoms persisted . An integrated neuro-immuno-gastroenterological approach is essential in such complex presentations. Figure: Smallbowel Figure: Autoimmune"

Clinical • Constipation • Crohn's disease • Diabetes • Endocrine Disorders • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Metabolic Disorders • Secondary Hyperparathyroidism • IL13 • IL6

The Forgotten Vagus: Recognizing Gastroparesis Following Radiofrequency Ablation for PVCs: An Unusual Complication (ACG 2026) - "The patient was referred to gastroenterology where she was initiated on pro-kinetic agents including prucalopride and alternating metoclopramide and erythromycin, with improvement in her symptoms at her 6-month follow-up. The temporality of symptom development following ablation argues for potential thermal-injury mediated gastroparesis. To our knowledge, this is one of the first instances of PVC ablation-mediated gastroparesis and establishes an important consideration for physicians who complete ablative procedures."

Atrial Fibrillation • Cardiovascular • Gastrointestinal Disorder • Thermal Injury • Ventricular Tachycardia

A Rare Presentation of Pelvic Pain as the Predominating Symptom of Superior Mesenteric Artery Syndrome With Concomitant Nutcracker Phenomenon: A Case Report (ACG 2026) - "The patient experienced early satiety, nausea and vomiting as well as concomitant constipation predominant irritable bowel syndrome (IBS-C) managed with prucalopride...It is important for health care providers to be aware of the condition and its clinical associations so that diagnosis can be reached sooner to prevent unnecessary delay in care and potentially deleterious outcomes. Figure: Aortomesenteric angle Figure: Left renal vein compressed between the SMA and aorta"

Case report • Clinical • Colorectal Cancer • Constipation • Endometriosis • Gastroenterology • Gastrointestinal Disorder • Gynecology • Immunology • Musculoskeletal Pain • Pain • Women's Health

Treatment Outcomes of Prucalopride in Children With Ineffective Esophageal Motility (ACG 2026) - "A total of 102 pediatric patients (52% female, median age 14 years (IQR: 7-16 years)) were included (56 conventional therapy; 46 prucalopride). Baseline demographic and clinical characteristics, including age, sex, comorbidities, GERD diagnosis and treatment, were similar between groups. Mean distal contractile integral was numerically higher in the prucalopride group (542.8±369.3 vs 429.2±241.9 mmHg·s·cm, p=0.082)."

Clinical • Gastroesophageal Reflux Disease • Gastrointestinal Disorder

DOES SIZE MATTER? THE COMBINED EFFECT OF CAPSULE DOWNSIZING AND PRUCALOPRIDE ON TRANSIT TIMES IN SMALL BOWEL CAPSULE ENDOSCOPY (UEGW 2026) - No abstract available

Methodological Considerations in Interpreting the Efficacy of Prucalopride for Bowel Preparation Before Colonoscopy. (PubMed, J Gastroenterol Hepatol) - No abstract available

Journal

Advances in the Treatment of Refractory Pediatric Constipation (PubMed, Acta Gastroenterol Latinoam) - "Amongthe innovative medications, prosecretory agents like linaclotide(already approved for children over 6 years old), lubiprostone andplecanatide, wich increase intestinal secretion, stand out. Other drugs,such as prucalopride (5HT-4 agonist) and pyridostigmine, aim to improvemotility...There are therapies thathave been little explored but show promise for the future, such asvibrating capsules, magnetic neurostimulation, and mind-body approacheslike hypnosis. Specific pediatric research and an individualizedtreatment approach are crucial to optimize adherence and outcomes inthese complex patients."

Journal • Review • Constipation • Gastroenterology • Gastrointestinal Disorder • Pediatrics

Alembic Pharmaceuticals Limited, a prominent player in the pharmaceutical industry, has announced receiving final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Prucalopride Tablets, 1 mg and 2 mg. (Business Upturn) - "This approval confirms the therapeutic equivalence of Alembic’s product to the reference listed drug product, Motegrity Tablets, 1 mg and 2 mg, developed by Takeda Pharmaceuticals USA Inc...Prucalopride, a serotonin-4 receptor agonist, is indicated for the treatment of chronic idiopathic constipation (CIC) in adults."

ANDA • Constipation

Use of Prucalopride in Severe Ileus in a Critically Ill Patient With Acute Alcoholic Hepatitis and Hepatic Encephalopathy. (PubMed, ACG Case Rep J) - "Prucalopride may be a potential therapeutic option for severe small bowel and colonic ileus in critically ill patients. Further studies are warranted to delineate its safety and efficacy."

Journal • CNS Disorders • Hepatic Encephalopathy • Hepatology • Inflammation • Metabolic Disorders

Prokinetic drugs that stimulate 5-HT4-serotonin receptors in the human atrium. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "Several gastrointestinal drugs like bromopride, cinitapride, cisapride, clebopride, felcisetrag, metoclopramide, mosapride, naronapride, prucalopride, renzapride, tegaserod, velusetrag, and zacopride are probably agonists at 5-HT4-serotonin receptors in the intestine. We will present our view where there are remaining pre-clinical or clinical research needs. One may repurpose some of these drugs to act on cardiac 5-HT4-serotonin receptors and discuss for which indications this may offer additional benefits."

Journal • Review

Magnetic particle imaging tracers for human applications: preclinical in vivo evaluation of Magtrace, Resotran, and FerroTrace. (PubMed, Npj Imaging) - "Feasibility of clinical-scale MPI for complex lymphatic mapping was demonstrated using a human-sized head-and-neck phantom modeling bilateral lymphatic drainage. Together, these results establish Magtrace, Resotran, and FerroTrace as suitable magnetic tracers for MPI lymphography and support their use in future human MPI applications."

Journal • Preclinical • Breast Cancer • Oncology • Solid Tumor

Editorial: Comparative Effectiveness in Chronic Constipation-Interpreting Real-World Evidence. (PubMed, Aliment Pharmacol Ther) - No abstract available

HEOR • Journal • Real-world evidence • Constipation • Gastroenterology • Gastrointestinal Disorder

Precision Network Pharmacology Revealed by High-throughput Blind Docking: Deciphering the Multitarget Synergy of Taohe Chengqi Decoction against Constipation. (PubMed, Curr Comput Aided Drug Des) - "The innovative integration of machine learning-driven high-throughput blind docking technology with network pharmacology establishes a novel paradigm for traditional Chinese medicine research, significantly enhancing target prediction reliability through advanced structural validation."

Journal • Constipation • Gastroenterology • Gastrointestinal Disorder • Inflammation • IL17A • MAPK3

Elobixibat Versus Prucalopride in Functional Constipation: A Prospective Comparative Effectiveness Study. (PubMed, Aliment Pharmacol Ther) - "This head-to-head comparative study demonstrates that elobixibat provides superior overall symptomatic relief and quality-of-life improvement compared with prucalopride, potentially due to its dual mechanism of action. These findings support the consideration of IBAT inhibition as a second-line treatment option in patients with FC."

HEOR • Journal • Constipation • Gastroenterology • Gastrointestinal Disorder

Effects on hippocampal activity following novel 5-HT4 receptor agonism in unmedicated patients with depression: the RESTAND study. (PubMed, Transl Psychiatry) - "In this double-blind, randomised experimental medicine study, 52 right-handed, unmedicated individuals with MDD received 6-9 days of the 5-HT4R agonist PF-04995274 (15 mg, once daily) or placebo. This replicates and extends previous findings in healthy volunteers using prucalopride, and is consistent with preclinical evidence establishing a key role for 5-HT4Rs in hippocampal-dependent learning and memory. This translational evidence supports a role for 5-HT4R activation in modulating memory-related brain circuits in MDD and previously identified beneficial effects of another 5-HT4 receptor agonist, prucalopride, on cognitive performance."

First-in-human • Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Pro-cognitive effects of 5-HT4 receptor agonism in individuals with remitted depression. (PubMed, Psychol Med) - "Short-term 5-HT4R agonism improved performance on multiple objective cognitive measures in individuals with remitted depression. These findings replicate our previous results in healthy volunteers showing a pro-cognitive effect of prucalopride and support a role for 5-HT4Rs as a promising target for cognitive enhancement in mood disorders."

Clinical • Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Depression • Mood Disorders • Psychiatry

Dup15q model mice exhibit impaired gastrointestinal motility and a constipation-like phenotype, alleviated by prucalopride. (PubMed, Transl Psychiatry) - "15q dup mice exhibit constipation-like gastrointestinal dysfunction, and prucalopride alleviated their delayed transit and improved social behaviour. These findings highlight a potential avenue for symptom-focused intervention in this model."

Journal • Preclinical • Autism Spectrum Disorder • CNS Disorders • Constipation • Developmental Disorders • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Psychiatry